Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438
Date | 03 March 2015 |
Event | 13th International Congress on Targeted Anticancer Therapies |
Session | Epigenetics and chaperones |
Topics | Anti-Cancer Agents & Biologic Therapy Drug Development |
Presenter | Vincent Ribrag |